<DOC>
	<DOC>NCT01795105</DOC>
	<brief_summary>This is a Post-Marketing Surveillance study of Abilify® tablets in accordance with Korean regulations on New Drug Re-examination (i.e. New Drug Re-examination Standards: KFDA Notification No. 2010-94 dated 27 December 2010).</brief_summary>
	<brief_title>ABF Tourette's Disorder PMS</brief_title>
	<detailed_description>This study will be conducted in a prospective, single-arm, multi-center format. As this study is observational in nature, the patient's follow-up is not prescriptive in nature and must be left up to the judgment of the physician (investigator), within the period of observation set forth in the protocol.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Tourette Syndrome</mesh_term>
	<criteria>Pediatric patients 6 to 18 years of age with Tourette's Disorder Patients who are prescribed Abilify® treatment as per investigator's medical judgment. Patients who gave written authorization to use their personal and health data Patients starting Abilify® treatment after agreement is in place Patients with known hypersensitivity to Aripiprazole or any excipients of Abilify® Patients who have been treated with Abilify® Patients with rare hereditary problems of galactose intolerance, the lapp lactase deficiency, or glucosegalactose malabsorption Patients with score 0(Not assessed) or 1(Normal, not at all ill) in the TSCGIS Patients participating in other clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>